Business
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manu
About this update from Syngene International Ltd.
[{"type":"image","alt":"Biodexa Pharmaceuticals PLC","displaySize":"","headline":null,"caption":"Biodexa Pharmaceuticals PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/cf8020230030b56d2025ee88a941398b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sUUDgnq3ro8Cvn34_A5W5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/cf8020230030b56d2025ee88a941398b","width":300,"height":300}},"lazy":false},{"type":"text","content":"April 2, 2026","length":13,"tagName":"p"},{"type":"text","content":"Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies ","length":93,"tagName":"p"},{"type":"text","content":"Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) (“Syngene”) for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.","length":465,"tagName":"p"},{"type":"text","content":"Commenting, Dan Palmer, Vice President, Technology at Biodexa said “We are delighted to be partnering with Syngene for the second time. Syngene manufactured tolimidone dosage form for us on time and on budget and, given the license for MTX240 from Otsuka was only signed in early February, they have once again demonstrated their responsiveness and flexibility in designing a program to manufacture GMP product within only a few weeks” ","length":435,"tagName":"p"},{"type":"text","content":"About MTX240, its Unique Mechanism of Action, Clinical Rationale and Next StepsMolecular glue technology represents a novel approach that induces targeted protein interactions, offering a distinct mechanism of action to conventional kinase inhibitors for rare oncology indications.","length":282,"tagName":"p"},{"type":"text","content":"Gastrointestinal Stromal Tumors (“GIST”) is mostly driven by activating mutations in the KIT and/or PDGFR receptor tyrosine kinase. While tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib are reported to have significantly improved outco...